

Od: Therapeutic Advances in Psychopharmacology <onbehalf@manuscriptcentral.com>

Odesláno: 14. ledna 2026 9:42

Komu: anonymizováno

Předmět: Therapeutic Advances in Psychopharmacology - Decision on Manuscript ID TPP-25-OA-0090.R1

14-Jan-2026

Dear *anonymizováno*,

It is a pleasure to accept your manuscript entitled "Sympathetic activation but not dissociation linked to ketamine's sustained antidepressant effect" in its current form for publication in Therapeutic Advances in Psychopharmacology. The comments of the reviewer(s), if any, who reviewed your manuscript are included at the foot of this letter.

We value your feedback! If you have any comments on the publishing process, please do let us know.

To boost the visibility of the published papers, we promote the journal articles on our Twitter channel (@TAPsychoPharm) soon after publication. If you have a Twitter handle, please feel free to send it to the Managing Editor (shasha.sharief@sagepub.co.uk) so we can include you in our Tweets. We also encourage authors to share these tweets, as well as the article, to promote their work and widen the publication's reach.

Thank you again for your fine contribution. On behalf of the Editors of Therapeutic Advances in Psychopharmacology, we look forward to your continued contributions to the Journal.

Sincerely,

James Rucker
Associate Editor

David Taylor
Editor-in-Chief

Therapeutic Advances in Psychopharmacology
tpp@sagepub.co.uk

Reviewer(s)' Comments to Author:

Reviewer: 1

Comments to the Author
No further questions/comments

Reviewer: 2

Comments to the Author

I thank the authors for addressing my points and have no further comments

Editor(s)' Comments to Author:

Associate Editor

Comments to the Author:

Congratulations!

--

Tato zprava byla prohledana na vyskyt viru
a nebezpecneho obsahu antivirovym systemem
MailScanner a zda se byt cista.